KalVista Pharmaceuticals, Inc. (KALV) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is held by 146 institutional firms.

• Institutional ownership in KalVista Pharmaceuticals edged up to 123.2% in September 2025, compared to 109.9% in June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 12.27%, with a year-over-year an increase of 20.66% in the count of filers.
• Among the 146 institutional holders of KalVista Pharmaceuticals, 75 added to their stakes while 45 trimmed their positions and 26 held steady.
• This class of investors increased its holdings in KalVista Pharmaceuticals to 62.23Mn shares for the 13F-cycle ending September 2025, up by 6.80Mn shares quarter on quarter, and up 13.35Mn shares year over year.
• VR Adviser, LLC's holding of 6.73Mn shares as of September 30, 2025 makes it the primary institutional investor in KalVista Pharmaceuticals, owning 13.32% of the stock.
• Among the most significant buyers of KalVista Pharmaceuticals during September 2025 were TUDOR INVESTMENT CORP ET AL (2.00Mn), MILLENNIUM MANAGEMENT LLC (1.69Mn), GOLDMAN SACHS GROUP INC (1.67Mn), Caption Management, LLC (1.14Mn), Parkman Healthcare Partners LLC (1.06Mn).
• Leading sellers of KalVista Pharmaceuticals stock in September 2025 included Vestal Point Capital, LP (3.92Mn), JANUS HENDERSON GROUP PLC (1.13Mn), AMERIPRISE FINANCIAL INC (909.68K), SILVERARC CAPITAL MANAGEMENT, LLC (468.79K), STEMPOINT CAPITAL LP (330.02K).
• The top 10 institutional holders of KalVista Pharmaceuticals for the quarter ending September 2025 included VR Adviser, LLC (6.73Mn), TANG CAPITAL MANAGEMENT LLC (5.04Mn), Frazier Life Sciences Management, L.P. (5.04Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (4.77Mn), Capital World Investors (3.18Mn), BlackRock, Inc. (3.13Mn), VANGUARD GROUP INC (2.50Mn), MILLENNIUM MANAGEMENT LLC (2.12Mn), TUDOR INVESTMENT CORP ET AL (2.00Mn), Woodline Partners LP (1.92Mn).